Occlusion time | Amount of lymphocytes (days of survival) | Marker | n | Strain | Reference | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 | <1 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 14 | ≥30 |  |  |  |  |
60Â minutes | - | +++ | Â | Â | Â | Â | Â | Â | Â | Â | CD3 | 6 | C57Bl/6 | [42] |
60Â minutes | - | - | + | +++ | ++ | Â | Â | Â | Â | Â | CD3 | 6 | C57Bl/6 | [34] |
pMCAO | Â | - | Â | Â | Â | +++ | Â | Â | Â | Â | CD3 | 8 | C57Bl/6 | [43] |
pMCAO | +++ | ++ | Â | ++ | Â | Â | Â | ++ | Â | Â | CD3 | ns | CB17 | [44] |
pMCAO | - | + | + |  |  |  | +++ |  |  |  | CD3 | 6 | Sprague–Dawley | [45] |
pMCAO | Â | + | Â | ++ | Â | Â | Â | +++ | ++ | + | CD5 | 5 | Wistar | [41] |
120Â minutes | +++ | ++ | Â | + | Â | Â | Â | Â | Â | Â | CD4 | 8 | Wistar | [37] |
pMCAO | ++ | ++ | Â | ++ | Â | Â | Â | Â | ++ | Â | CD4 | ns | CB17 | [44] |
120Â minutes | - | - | Â | +++ | Â | Â | Â | Â | Â | Â | CD8 | 8 | Wistar | [37] |
pMCAO | Â | Â | + | Â | ++ | Â | Â | +++ | ++ | - | CD8 | 5 | Wistar | [41] |
60Â minutes | Â | - | - | - | + | +++ | Â | Â | Â | Â | B220 | 6 | C57Bl/6 | [34] |
pMCAO | Â | Â | - | Â | Â | +++ | Â | Â | Â | Â | B220 | 8 | C57Bl/6 | [43] |